It is a long way – but it is worth it
ArcticZymes Technologies supports the United Nations' 17 Sustainable Development Goals.
We focus on long-term and sustainable relationships with our business partners and commercial innovators around the world. Therefore, we are constantly striving to work at the highest level and not only meet minimum demands, but to exceed the expectations of our partners.
In doing so, we always ensure that our operations do not significantly impact the ecosystem and that our growth does not have any negative impact on the environment or biodiversity.
Quality and product safety are at the heart of everything we do. Ensuring high quality is part of our DNA and runs through the entire process – from discovery to research and development to production.
Facts about ESG at ArcticZymes
Quality management system
ArcticZymes Technologies has implemented a comprehensive quality management system to ensure that the products developed, manufactured and sold are of high quality and safe for users and patients.
The quality management system is based on the principles of current good manufacturing practice (cGMP) and the requirements defined in the ISO 13485 standard.
Our business model is designed to minimize negative impacts on biodiversity and the use of resources from natural raw materials.
ArcticZymes' materiality analysis process involved using internal and external resources to identify our potential impacts on environmental, social and governance aspects. The process included dialogue with key stakeholders from six identified key stakeholder groups.
Prioritization & governance
To better understand the impact of what we create and our ability to contribute to a healthier world, we need to align our performance with the expectations of our key stakeholders.
Our prioritization of key issues therefore included surveys of more than 170 stakeholders from six stakeholder groups to capture importance from different perspectives.
ArcticZymes has an ambitious innovation pipeline to expand the product range. Our goal for the next 2–6 years is to be able to offer our customers a complete portfolio of synergistic enzymes for the different markets we serve.
Our innovation activities are supported by collaborative projects with national and international partners, and more than 36% of our employees are involved in research and development.
The future of the company and its ability to attract and retain a skilled workforce are critical to its success. We promote an active dialogue between all levels of the company, pay attention to employee well-being and encourage all employees to work towards better health, both physiological and physical. We strongly believe in the diversity and continuous development of our employees. We are committed to applying equal rights, responsibilities and opportunities and to promoting the personal development of all our employees.
The raw materials for our enzyme production are manufactured in closed systems by cultivating microorganisms that have been genetically modified to produce the enzymes.
Thus, the company does not harvest any material from nature or take advantage of natural areas to obtain raw materials. The raw materials used for in-house cultivation are standard inorganic, organic chemicals and protein hydrolysates, totaling less than 100 kg/year. Emissions from upstream production (cultivation) are modest amounts of carbon dioxide and inactivated (autoclaved) microorganisms. After inactivation, organic waste that may contain microorganisms is shipped as hazardous waste to external recipients for proper destruction.
Our partnership approach
We are driving long-term relationships, making sure our partners are aligned with our values and putting our customers' needs at the center of what we do.